Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07421375 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions | PHASE1 | NOT YET_RECRUITING | 58 | — | — | Apr 2, 2026 | May 31, 2026 | Feb 19, 2026 | - | — |
Area under the Plasma Concentration-Time Curve from Time Zero to Time t of Fimasartan
Area under the Plasma Concentration-Time Curve from Time Zero to Time t of Indapamide
Maximum Concentration of Drug in Plasma of Fimasartan
Maximum Concentration of Drug in Plasma of Indapamide
| Arm | Type | Description |
|---|---|---|
| BR1015-A | EXPERIMENTAL | - |
| BR1015-1+BR1015-2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BR1015-A | DRUG | One tablet administered alone |
| BR1015-1 | DRUG | One tablet administered alone |
| BR1015-2 | DRUG | One tablet administered alone |
Inclusion Criteria: * Subjects with a body mass index (BMI) of more than 18.0 kg/m² and less than 30.0 kg/m² at the screening visit. * Subjects who provide written informed consent voluntarily after receiving and understanding sufficient explanation regarding the purpose and procedures of the clini...